---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000140"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:43:39.882220+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise

## Summary
- Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.
- Bot brings three decades of R&D experience in CAR T, cell/gene therapy and nanomedicines; former CSO of Capstan Therapeutics.
- Initial compensation includes option for 17,200 shares at $8.29 and RSUs for 5,800 shares, with multi-year vesting schedules.
- CEO highlights Bot's role in first-in-class CAR T therapies and Capstan's acquisition by Abbvie, relevant to Cartesian's autoimmunity focus.
- Company is a clinical-stage biotech advancing cell therapy for autoimmune diseases; expects a critical year of execution.

## SEC filing metadata
- accession: 0001453687-25-000140
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.05, 7.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/0001453687-25-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/rnac-20251216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000140
- JSON: https://secwatch.observer/filing/0001453687-25-000140.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.